We have previously discussed Berberine on this forum as potentially useful against PD as well as having a multitude of other positive health effects in many various health conditions. This new study (April, 2024) suggests that Berberine may have anti-AD effects worth considering, at least in a mouse model of AD.
' Berberine (BBR) treatment shows promise in alleviating Alzheimer's disease (AD) by targeting gut microbiota and modulating the gut-brain axis. '
' BBR treatment effectively clears Aβ plaques, reduces neuroinflammation, and improves spatial memory dysfunction in AD mice. '
' BBR treatment alleviates intestinal inflammation, enhances intestinal permeability, and positively influences the composition and metabolites of the gut microbiota. '
' These findings highlight the potential role of gut microbiota modulation in AD therapy and support the use of BBR as a therapeutic agent for AD. '
This study further elucidates again, how Berberine works via a positive manipulation of the gut microbiome.
Berberine is quite a remarkable compound for human health worthy of serious consideration in a rather wide array of health issues!
Art
Written by
chartist
To view profiles and participate in discussions please or .
The dose often recommended in studies for diabetes is 1500 mg/day in three divided doses of 500 mg at breakfast, lunch and dinner. That is the dose I use, but it is usually better to start at 500 mg/day and work up slowly to allow the gut microbiome to adjust slowly to the intake of berberine.
I just happened to be updating my Berberine page. So much good stuff. I take 1200 mg a day. 800 in the morning and 400 at night. This is the easiest place to read my Berberine notes: rbd-pd-protocols.blogspot.c...
I'm not hypoglycemic. I also only have a high school degree. Everybody needs to decide what is best for them using their information and medical advisors.
When you look at the most common comorbidities of AD and PD as discussed in the following links and compare the value of Berberine to that list, the truer value of berberine in AD becomes much more apparent :
' The most common types of comorbidities that are seen along dementia in the elderly population include Parkinson's Diseases, Hypertension, Diabetes Osteoporosis, Chronic Ulcers of the skin, Thyroid diseases, Anxiety, Depression, Neurosis, Cardiovascular disorders, Anemia, Hypertrophy of the Prostate in males, and Retinal diseases. '
Taking this a step further to include PD and you can see once more that the true value of Berberine in PD is much more than beneficial effects against just PD. The following link discusses the comorbidities of PD :
Here is a relevant quote from the link which mentions many common comorbidities of PD :
' The most frequent comorbidities for the PD patients were cerebrovascular disease (42.53%), hypertension (33.17%), diabetes (10.60%), chronic pulmonary disease (6.98%) and paralysis (5.53%). For the Parkinsonism patients, cerebrovascular disease (53.22%), hypertension (39.00%), diabetes (11.66%), paralysis (11.06%) and dementia (7.05%) were more common. Parkinsonism patients more frequently had cerebrovascular disease, dementia, paralysis, hypertension, weight loss, and drug abuse than patients with PD, but they had a lower prevalence of solid tumor without metastasis and mild liver disease (see Supplementary Table S1). These results indicated that the comorbidity burden is relatively heavier in Parkinsonism patients than in patients with PD. '
Taking into consideration all of the above mentioned comorbidities of AD and PD and comparing those to studies involving Berberine and most of the listed comorbidities, you start to get a much better idea of just how valuable Berberine is when it comes to AD and PD. Berberine is a truly versatile and remarkable compound!
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
FMT should be listed among the most urgent therapeutic trials
